文献速递支持与姑息治疗

欧洲患者造血干细胞移植后第二实体癌的评估

Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients.
PubMed 文献 · JAMA Oncol · 2019-01-01

该队列研究纳入欧洲26国220617例移植患者中4065例(1.8%)移植后第二实体癌患者,5年年龄标化总生存率为47%(95%CI 45%-49%),生存主要取决于第二癌类型,黑色素瘤、前列腺癌、乳腺癌、肾癌、膀胱癌、结直肠癌和子宫内膜癌的标准化死亡比高于原发实体癌。

要点

  • 移植后第二实体癌5年年龄标化总生存率为47%(95%CI 45%-49%)。
  • 胰腺癌、肺癌、肝胆癌、食管癌、脑癌和胃癌中位生存仅0.6至1年。
  • 黑色素瘤、前列腺癌、乳腺癌、肾癌、膀胱癌、结直肠癌和子宫内膜癌标准化死亡比高于原发实体癌。

核心结论

  • 第二实体癌的结局主要取决于第二癌类型,未来研究应探究某些癌种标准化死亡比更高的原因,以明确这些患者是否应接受不同治疗,并帮助筛查和咨询移植后发生第二实体癌的患者。

研究设计与样本

  • 该队列研究使用欧洲血液与骨髓移植学会注册数据,纳入26国220617例移植患者中2000年1月1日至2014年12月31日诊断第二实体癌的4065例患者,涵盖18种癌症,数据分析时间为2017年9月3日至2018年3月17日。

主要发现

  • 4065例第二实体癌患者中男性2321例(57.1%)、女性1744例(42.9%),诊断第二实体癌时平均年龄59.1岁(范围3.2-82.3岁)。
  • 5年年龄标化总生存率为47%(95%CI 45%-49%)。
  • 胰腺癌、肺癌、肝胆癌、食管癌、脑癌和胃癌的5年总生存率差,中位生存0.6至1年。
  • 子宫内膜癌、结直肠癌、肉瘤、卵巢癌、膀胱癌、口咽癌和肾癌的5年总生存率居中,中位生存2至10年。
  • 黑色素瘤、乳腺癌、前列腺癌、宫颈癌和甲状腺癌的5年总生存率较好,中位生存10年或以上。

关键数值与推荐

  • 共1777例(43.7%)死亡,其中1256例(74.8%)死于第二实体癌,344例(20.5%)死于原发病,79例(4.7%)死于其他原因。
  • 接受异基因造血干细胞移植患者的额外移植相关死亡因素包括移植时年龄、供者类型、预处理方案和移植物抗宿主病。
  • 黑色素瘤、前列腺癌、乳腺癌、肾癌、膀胱癌、结直肠癌和子宫内膜癌的标准化死亡比高于原发实体癌,其他癌症未见升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Incidence and risk factors of second solid cancers (SSCs) that occur after hematopoietic stem cell transplantation (HSCT) are well documented. However, clinical outcome data of patients who developed an SSC after HSCT are limited. OBJECTIVE: To assess the outcome of patients with an SSC occurring after HSCT from the time of SSC diagnosis. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data of 4065 patients from 26 countries registered with the European Society for Blood and Marrow Transplantation, which has maintained clinical data since 1977 of patients who received a transplant. Information from all patients who underwent a transplant in Europe and had an SSC diagnosis between January 1, 2000, and December 31, 2014, was extracted. The cohort included patients with 18 different cancers. Data analysis was conducted from September 3, 2017, to March 17, 2018. MAIN OUTCOMES AND MEASURES: Median and 5-year age-standardized overall survival, causes of death, risk factor multivariate analysis using a clustered Cox proportional hazard regression model, and standardized mortality ratio were calculated for each of the 18 types of SSC. RESULTS: In total, 220 617 patients underwent a transplant, of whom only 4065 (1.8%) patients with a second solid cancer after HSCT were included in the study. Among the 4065 patients, 2321 (57.1%) were men and 1744 (42.9%) were women, with a mean (range) age of 59.1 (3.2-82.3) years at diagnosis of second solid cancer. The 5-year age-standardized overall survival was 47% (95% CI, 45%-49%). The 5-year overall survival rate after SSC diagnosis was poor for pancreas, lung, hepatobiliary, esophageal, brain, and gastric cancers, with a median survival between 0.6 and 1 year. The 5-year overall survival was intermediate for endometrial, colorectal, sarcomas, ovarian, bladder, oropharyngeal, and kidney cancers, with a median survival between 2 and 10 years. The 5-year overall survival was more favorable for melanoma, breast, prostate, cervix, and thyroid cancers, with a median survival of 10 or more years. Additional transplant-associated factors for mortality for patients treated with allogeneic HSCT were age at transplant, donor type, conditioning regimen, and graft-vs-host disease. In total, 1777 patients (43.7%) died, of which 1256 (74.8%) were from SSC, 344 (20.5%) from primary disease, and 79 (4.7%) from other causes. Standardized mortality ratio was higher, compared with de novo solid cancers, for melanoma, prostate, breast, kidney, bladder, colorectal, and endometrial cancers but not for the other cancers. CONCLUSIONS AND RELEVANCE: The outcome of SSC is mainly dependent on the type of second cancer; thus, future studies should investigate the reasons the standardized mortality ratio is higher for some cancers to identify whether patients with these cancers should be treated differently and to help in screening and counseling patients who developed an SSC after HSCT.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tichelli A, Beohou E, Labopin M, et al. Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. JAMA Oncol. 2019. PMID: 30476975. doi:10.1001/jamaoncol.2018.4934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。